Current and Long- Term Liabilities

3 Months Ended

Mar. 31, 2018

CURRENT AND LONG-TERM LIABILITIES

Accrued Expenses

Accrued expenses consisted of the following as of March 31, 2018 and December 31, 2017 (in thousands):



	March 31, 2018		December 31, 2017
Commercial rebates, fees and returns	$	114,884	$	102,357
Professional, license, and other fees and expenses	29,033		28,692
Salaries, bonuses, and other compensation	14,034		19,099
Interest expense	6,639		13,525
Bremelanotide milestone payment	20,000		—
Intrarosa-related license fees	10,000		10,000
Accrued research and development	4,481		1,817
Total accrued expenses	$	199,071	$	175,490

Deferred Revenues

Our deferred revenue balances as of March 31, 2018 and December 31, 2017 of $69.9 million and $66.9 million, respectively, were primarily related to our CBR Services revenues and included: (a) amounts collected in advance of unit processing and (b) amounts associated with unearned storage fees collected at the beginning of the storage contract term, net of allocated discounts.